Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$2.90 USD
+0.06 (2.26%)
Updated Apr 26, 2024 12:24 PM ET
After-Market: $2.91 +0.01 (0.20%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AYTU 2.90 +0.06(2.26%)
Will AYTU be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AYTU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AYTU
ANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue Estimates
Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AYTU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aytu BioPharma Inc. (AYTU), Here's Why It's a 'Buy' Now
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?
Other News for AYTU
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
Maxim Group Remains a Buy on Aytu BioScience (AYTU)
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
Earnings Scheduled For February 14, 2024